1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsDevelopment of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases (DMID RA 004) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID). This program supports the advanced development of therapeutic products for biodefense, anti-microbial resistant (AMR) infections, and emerging infectious diseases.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Deadline for NIAID BAA Proposals: Therapeutic Products for Biodefense, AMR Infections, and Emerging Infectious Diseases Deadline for NIAID BAA Proposals: Therapeutic Products for Biodefense, AMR Infections, and Emerging Infectious Diseases Research Area 004: Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections, and Emerging Infectious Diseases Supports development of promising new therapeutics to address infections caused by NIAID Category A, B, and C priority pathogens and select bacterial and fungal infections identified in CDC’s report Antibiotic Resistance Threats in the United States 2019 , including optimization, preclinical (investigational new drug-enabling), and clinical trials that include Phase I and Phase II studies.
Due Date: April 9, 2020 , by 3 p. m. Eastern Time Global Biodefense provides this information as a courtesy.
Information is subject to change. Please check the funding opportunity sponsor website to verify the most current status. Event Category: Deadlines https://globalbiodefense.
com/funding/2020-niaid-omnibus-broad-agency-announcement/ Global Biodefense Calendar National Institute of Allergy and Infectious Diseases (NIAID) Type above and press Enter to search. Press Esc to cancel.
According to the current listing, eligibility includes: Institutions and organizations, including international, that can conduct research and development of therapeutic products. Specific eligibility for Canadian biotechnology companies should be confirmed with NIAID. Confirm the full requirements in the official notice before applying.
Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases (DMID RA 004) is funded by National Institute of Allergy and Infectious Diseases (NIAID). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articleThe ReVAMPP network funds vaccine and monoclonal antibody research across five virus families. Here is who won, what the prototype-pathogen strategy means, and how to position for the next round.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read article